SCHEMBL6340738

SCHEMBL6340738

Cn1ncc2cc(CCCN)ccc21

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 1/20 0.56
TCF7 P36402 1/20 0.56
MPO P05164 1/20 0.46
DRD4 P21917 3/20 0.42
SIGMAR1 Q99720 2/20 0.42
TMEM97 Q5BJF2 1/20 0.42
CCNC P24863 2/20 0.40
CDK8 P49336 2/20 0.40
HTR2A P28223 1/20 0.40
PASK Q96RG2 1/20 0.40
CDK19 Q9BWU1 1/20 0.40
KDM1A O60341 4/20 0.40
CACNA1H O95180 5/20 0.40
CACNA1G O43497 3/20 0.40
CACNA1I Q9P0X4 3/20 0.40
CDC7 O00311 1/20 0.40
TRPM5 Q9NZQ8 1/20 0.40
AR P10275 1/20 0.39
TRPA1 O75762 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31638220 0.90 CTNNB1 (0.58) CTNNB1TCF7MPODRD4SIGMAR1
SCHEMBL13476250 0.90 CTNNB1 (0.58) CTNNB1TCF7MPODRD4SIGMAR1
SCHEMBL19991900 0.86 CTNNB1 (0.57) CTNNB1TCF7MPODRD4SIGMAR1
SCHEMBL14402843 0.84 CTNNB1 (0.56) CTNNB1TCF7MPODRD4SIGMAR1
SCHEMBL904751 0.83 CTNNB1 (0.54) CTNNB1TCF7MPODRD4SIGMAR1
SCHEMBL29728749 0.83 CTNNB1 (0.54) CTNNB1TCF7MPODRD4SIGMAR1
SCHEMBL8220146 0.82 CTNNB1 (0.59) CTNNB1TCF7MPODRD4SIGMAR1
SCHEMBL31638366 0.81 CTNNB1 (0.58) CTNNB1TCF7MPODRD4SIGMAR1
SCHEMBL8179108 0.78 CTNNB1 (0.55) CTNNB1TCF7MPODRD4SIGMAR1
SCHEMBL16406917 0.77 CTNNB1 (0.54) CTNNB1TCF7MPODRD4SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849649-B2 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. (US) 2005-02-01 US disclosed
US-20040106611-A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC 2004-06-03 US disclosed
EP-1373192-A1 N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD Pfizer Limited (GB) 2004-01-02 EP disclosed
US-6660756-B2 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. 2003-12-09 US disclosed
US-20030105132-A1 N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. 2003-06-05 US disclosed
WO-2002079143-A1 N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD PFIZER LIMITED (GB) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105132-A1 N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PREP, ENGASE, ENPEP CTNNB1 4752/4885TCF7 4432/4885MPO 801/4885
US-20040106611-A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PREP, ENGASE, ENPEP CTNNB1 4751/4885TCF7 4443/4885MPO 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.